A Landmark Funding Round Propels Nadler to Billionaire Status
Daniel Nadler, the visionary co-founder of OpenEvidence, has officially joined the billionaire club following a monumental $210 million Series B funding round for his AI-driven clinical decision support platform. The investment, co-led by industry giants Google Ventures and Kleiner Perkins, has catapulted OpenEvidence’s valuation to an impressive $3.5 billion. This milestone not only solidifies Nadler’s financial success but also highlights the transformative potential of his company in the healthcare sector.
Revolutionizing Healthcare with AI
OpenEvidence is reshaping how medical professionals access and apply knowledge. The platform provides clinicians with real-time, evidence-based insights, enabling them to make informed decisions at the point of care. With over 10,000 hospitals and medical centers nationwide adopting the technology, OpenEvidence has become an indispensable tool for physicians. Remarkably, more than 40% of U.S. doctors log in daily to leverage its capabilities.
The platform’s success lies in its ability to:
- Aggregate and organize vast amounts of medical research into actionable insights.
- Deliver instant recommendations tailored to individual patient cases.
- Reduce diagnostic errors and improve patient outcomes.
Nadler’s Journey: From Finance to Healthcare
Before revolutionizing healthcare, Nadler made waves in the financial sector. In 2013, he founded Kensho Technologies, an AI company specializing in financial analysis. Kensho’s groundbreaking machine learning systems caught the attention of S&P Global, which acquired the company in 2018 for $550 million—one of the largest AI deals of the decade.
Nadler’s transition from finance to healthcare underscores his ability to identify and solve complex problems across industries. His work has earned him a spot on the TIME100 Health list in 2025, recognizing his influence in global health innovation.
Comparing Nadler’s Ventures: Kensho vs. OpenEvidence
Nadler’s two major ventures, Kensho and OpenEvidence, share a common thread: leveraging AI to transform industries. Below is a comparison of their key milestones:
| Metric | Kensho Technologies | OpenEvidence |
|---|---|---|
| Founded | 2013 | 2020 |
| Industry | Financial Analysis | Healthcare |
| Acquisition/Funding | $550M (S&P Global, 2018) | $210M Series B (2023) |
| Valuation | Undisclosed (pre-acquisition) | $3.5B |
| Impact | Advanced AI for Wall Street | Transforming clinical decision-making |
The Future of OpenEvidence and Nadler’s Legacy
With its latest funding, OpenEvidence is poised to expand its reach globally, bringing its life-saving technology to more healthcare providers. Nadler’s journey from a fintech entrepreneur to a healthcare pioneer exemplifies the power of innovation and adaptability.
As OpenEvidence continues to grow, its mission remains clear: to empower clinicians with the tools they need to deliver better care. For Nadler, this achievement is not just about financial success—it’s about leaving a lasting impact on the world of medicine.
